Insulet envisions a world where advanced diabetes technology and education is obtainable to all people living with the disease. HealthTech for All reflects Insulet’s conviction that leadership means taking action to close gaps in care. By helping to reduce health barriers and disparites in underseved communities living with diabetes, we enable more people to live their best lives.
Our approach centers on identifying nonprofit partners that share our commitment to advancing healthcare access and building long term, high impact relationships. We prioritize organizations that provide community centered care through resources, tools, and services that engage and empower people in their health journeys.
Through our outreach, we build greater understanding of diabetes technology. When people are aware of options beyond multiple daily injections, they are better positioned to access advanced technology and achieve improved health outcomes.
Affordability and accessibility
The Insulet team works to expand product affordability and access so more people can benefit from simpler diabetes management and better health outcomes. Our goal is to enable Omnipod access for all people with diabetes who wish to use it.
As advocates for the diabetes community, we actively engage with people with diabetes, Podders, healthcare professionals, and partners to better understand their needs. As we continue our strong growth trajectory, we know innovative ideas and technologies will fuel our ongoing efforts to transform lives. In the U.S., we strive to remove financial barriers and increase access to Pod therapy for the diabetes community by offering an innovative pricing model and financial assistance programs.
Expanding our reach
We strive to break down barriers to Pod therapy. As we continue to innovate and advance our medical devices, we seek to make Pod therapy globally and universally accessible to people with diabetes requiring insulin.
Our partnerships with health authorities and industry associations help drive equitable access to diabetes management technology internationally. We work with governments, health technology assessment bodies, and payors to help them evaluate this technology. In doing so, we consider benefits to users, health and quality-of-life outcomes, and the impact on healthcare ecosystems.
Quotation
Expanding global access is about reducing the daily burden of diabetes and ensuring that people everywhere can benefit from high quality, life transforming innovation as we work to advance automated insulin delivery as the global standard of care.
Pat Crannell, Senior Vice President and Head of International